HealthBeacon (ISE:HBCN) - Share price, News & Analysis

HBCN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

HBCN Stock Overview

HealthBeacon plc, a digital therapeutics company, develops products for managing injectable medications for patients in the home in Europe, the United States, and Ireland.

Rewards

Earnings are forecast to grow 120.1% per year

Revenue grew by 83.7% over the past year

Risk Analysis

Does not have meaningful revenue (€2M)

Does not have a meaningful market cap (€47M)

HealthBeacon Competitors

IRIDEX

NasdaqGM:IRIX

US$44.5m

Trinity Biotech

NasdaqGS:TRIB

US$48.9m

Kewaunee Scientific

NasdaqGM:KEQU

US$50.8m

Boule Diagnostics

OM:BOUL

kr460.2m

Price History & Performance

Summary of all time highs, changes and price drops for HealthBeacon
Historical stock prices
Current Share Price	€2.74
52 Week High	€6.24
52 Week Low	€2.60
Beta	0
1 Month Change	5.39%
3 Month Change	-37.73%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-53.24%

Recent News & Updates

Jul 20

HealthBeacon (ISE:HBCN) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

	HBCN	IE Medical Equipment	IE Market
7D	0%	-1.9%	3.3%
1Y	n/a	-25.5%	-16.3%

Return vs Industry: Insufficient data to determine how HBCN performed against the Irish Medical Equipment industry.

Return vs Market: Insufficient data to determine how HBCN performed against the Irish Market.

Price Volatility

Is HBCN's price volatile compared to industry and market?
HBCN volatility
HBCN Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.8%
Market Average Movement	5.6%
10% most volatile stocks in IE Market	9.3%
10% least volatile stocks in IE Market	3.9%

Stable Share Price: Insufficient data to determine HBCN's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine HBCN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	57	Jim Joyce	https://www.healthbeacon.com

HealthBeacon plc, a digital therapeutics company, develops products for managing injectable medications for patients in the home in Europe, the United States, and Ireland. Its injection care management system tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence driven data analytics. The company also sells and leases medical adherence technology devices and injection care management systems.

HealthBeacon Fundamentals Summary

How do HealthBeacon's earnings and revenue compare to its market cap?
HBCN fundamental statistics
Market Cap	€46.55m
Earnings (TTM)	-€8.21m
Revenue (TTM)	€2.21m

21.0x

P/S Ratio

-5.7x

P/E Ratio

Is HBCN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
HBCN income statement (TTM)
Revenue	€2.21m
Cost of Revenue	€1.91m
Gross Profit	€301.00k
Other Expenses	€8.51m
Earnings	-€8.21m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.48
Gross Margin	13.60%
Net Profit Margin	-370.78%
Debt/Equity Ratio	0.03%

How did HBCN perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is HBCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HBCN?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for HBCN. This is calculated by dividing HBCN's market cap by their current preferred multiple.
What is HBCN's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	€46.55m

HBCN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.1x
Enterprise Value/EBITDA	-2.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HBCN's PS Ratio compare to its peers?

HBCN PS Ratio vs Peers

The above table shows the PS ratio for HBCN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	0.6x
IRIX IRIDEX	0.8x	8.6%	US$44.5m
TRIB Trinity Biotech	0.6x	5.5%	US$48.9m
KEQU Kewaunee Scientific	0.3x	n/a	US$50.8m
BOUL Boule Diagnostics	0.9x	6.2%	kr460.2m
HBCN HealthBeacon	21x	89.5%	€46.6m

Price-To-Sales vs Peers: HBCN is expensive based on its Price-To-Sales Ratio (21x) compared to the peer average (0.6x).

Price to Earnings Ratio vs Industry

How does HBCN's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Sales vs Industry: HBCN is expensive based on its Price-To-Sales Ratio (21x) compared to the European Medical Equipment industry average (5.8x)

Price to Sales Ratio vs Fair Ratio

What is HBCN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HBCN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	21x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HBCN's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of HBCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HBCN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HBCN's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is HealthBeacon forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

120.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HBCN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).

Earnings vs Market: HBCN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HBCN is expected to become profitable in the next 3 years.

Revenue vs Market: HBCN's revenue (89.5% per year) is forecast to grow faster than the Irish market (8.3% per year).

High Growth Revenue: HBCN's revenue (89.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HBCN's Return on Equity is forecast to be low in 3 years time (12%).

Discover growth companies

Past Performance

How has HealthBeacon performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-139.3%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: HBCN is currently unprofitable.

Growing Profit Margin: HBCN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if HBCN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare HBCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HBCN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).

Return on Equity

High ROE: HBCN has a negative Return on Equity (-28.05%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is HealthBeacon's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: HBCN's short term assets (€29.1M) exceed its short term liabilities (€3.6M).

Long Term Liabilities: HBCN's short term assets (€29.1M) exceed its long term liabilities (€112.0K).

Debt to Equity History and Analysis

Debt Level: HBCN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if HBCN's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HBCN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: HBCN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.9% each year

Discover healthy companies

Dividend

What is HealthBeacon current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate HBCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HBCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HBCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HBCN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HBCN has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure

CEO

Jim Joyce (51 yo)

9.58yrs

Tenure

Mr. James Joyce, also known as Jim, serves as Chief Executive Officer for HealthBeacon plc and has been its Executive Director since July 25, 2013. Mr. Joyce co-founded HealthBeacon plc in 2013. He served...

Leadership Team

Experienced Management: HBCN's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: HBCN's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: HBCN only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/08/17 00:00
End of Day Share Price	2022/08/04 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31